[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"addiction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:addiction":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,29,0,25,[9,48,81,105,127,176,200,226,248,281,310,351,385,413,440,472,496,518,547,573,601,619,645,668,691],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100517311","phase-2-semaglutide-therapy-for-alcohol-reduction-star-100517311",false,"NCT06015893","Semaglutide Therapy for Alcohol Reduction (STAR)","Semaglutide Therapy for Alcohol Reduction (STAR): A Proof-of-Concept Phase II Clinical Trial","* INCLUSION CRITERIA:\n\nThis study will enroll adult individuals with a current diagnosis of AUD. Participants will be recruited without any preference to sex, race, religion, or other social variables, but sociodemographic data will be collected for sample characterization and potential use in the analyses. Since self-reported psychological measures that have been validated in English constitute major part of the study assessments, participants need to be able to speak, read, write, and understand English to be in the study.\n\nThe information needed to assess eligibility will be collected under an IRB-approved NIDA IRP\n\nscreening protocol, led by the Office of the Clinical Director (OCD) at the NIDA IRP to assess\n\npotential research participants' eligibility for entering clinical protocols. Additional details can be found in the NIDA screening protocol documents. Furthermore, NIH medical records (from other NIH clinical protocols) and outside medical records may also be used, if available, to determine whether participants fulfill the eligibility criteria.\n\nTo be eligible for this study, an individual must meet all of the following criteria:\n\n* At least 18 years old\n* Alcohol Use Disorder (minimum 2 symptoms on a validated diagnostic tool, e.g., the Mini-International Neuropsychiatric Interview (MINI) or the Structured Clinical Interview for DSM Disorders (SCID))\n* Self-reported drinking, according to alcohol Timeline Follow-Back (TLFB), of \\> 7 drinks per week for females or \\> 14 drinks per week for males during the 28-day period prior to screening plus at least four days with \\> 3 drinks for females or \\> 4 drinks for males during the 28-day period prior to screening\n* Most recent Clinical Institute Withdrawal Assessment for Alcohol - revised (CIWA-Ar) score \\\u003C 10\n* Able to speak, read, write, and understand English as demonstrated by ability to understand and sign the NIDA screening protocol consent\n* Normal or corrected-to-normal (e.g., wearing glasses or contacts) vision and normal or corrected-to-normal (e.g., with the use of a hearing aid) hearing\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from enrolling in this study:\n\n* BMI \\\u003C 23 kg\u002Fm\\^2 or BMI \\>= 50 kg\u002Fm\\^2\n* Evidence of malnutrition as determined by the Nutrition Risk Screening 2002 (NRS-2002)\n* Most recent blood tests: creatinine \\>= 2 mg\u002FdL, eGFR \\\u003C45 mL\u002Fmin\u002F1.73 m\\^2, triglycerides \\> 500 mg\u002Fdl, ALP \\> 4x the upper limit of normal, clinically abnormal lipase levels per study clinician\n* Present diagnosis of diabetes mellitus or blood hemoglobin A1c (HbA1c) \\>= 6.5 %\n* Current (within the past 30 days) use of the following medications with glucose lowering properties: GLP-1 analogues, sulfonylurea, insulin, metformin, thiazolidinediones, dipeptidyl peptidase-4 (DPP-IV) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors\n* Current or prior use of semaglutide or tirzepatide\n* Current (within the past 30 days) use of weight-lowering medications\n* Current (within the past 30 days) use of FDA-approved pharmacotherapy for AUD (oral or intramuscular naltrexone, acamprosate, disulfiram)\n* Current (within the past 30 days) use of medications with known interaction with semaglutide\n* Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)\n* Known ongoing history of alcohol ketoacidosis, gastroparesis, pancreatitis (either acute or chronic), pancreatic carcinoma, gallbladder disease, jaundice, Mallory-Weiss syndrome (esophageal tears secondary to vomiting), esophageal varices, cirrhosis\n* Known history of gastric bypass surgery\n* Known history of prior hypersensitivity reaction to semaglutide, any of the product components, or any other GLP-1 analogue\n* Known history of suicidal attempts (within the past 24 months) or active suicidal ideation\n* Known history of clinically significant vestibular disorders or motion sickness\n* Known history of clinically significant noise-induced hearing loss or tinnitus\n* Contraindication(s) for brain fMRI\n* Unstable cardiovascular conditions (e.g., arrhythmias, clinically significant ECG abnormalities)\n* Physical and\u002For mental health conditions that are clinically unstable, as determined by the study clinicians, including (but not limited to) major depressive disorder or generalized anxiety disorder unstable during the past three months or other psychiatric conditions (e.g., schizophrenia, bipolar disorder) unstable during the past twelve months prior to screening.\n* Female who is pregnant, breast-feeding, or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method\n* Any other reason or clinical condition that the investigators judge may interfere with study participation and\u002For be unsafe for a participant","ALL","18 Years","110 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Background:\n\nAlcohol use disorder (AUD) is a problematic pattern of alcohol use accompanied by clinically significant medical consequences. Medications can help most people reduce their drinking, but the number is limited, and additional treatment options are needed.\n\nObjective:\n\nTo test if a medication named Semaglutide may reduce alcohol drinking in people with AUD.\n\nWho can participate?\n\nAll Adults aged 18 or older with AUD might be eligible to participate in the study.\n\nWhat will happen during the study?\n\nParticipants will visit the National Institute on Drug Abuse (NIDA) in Baltimore once a week for about 20 weeks (5 months). Each visit will last between 2 and 6 hours depending on the tasks scheduled for that visit.\n\nParticipants will be assigned by chance (like flipping a coin) to receive either Semaglutide or placebo. A placebo looks just like a real drug but contains no medicine.\n\nThe study medication is given as a shot under the skin each week.\n\nParticipants will undergo different tests throughout the study:\n\nThey will give blood, urine, and saliva samples.\n\nThey will engage in self-paced behavioral therapy on a computer.\n\nThey will answer questions about their mood, diet, alcohol drinking and craving, tobacco use, etc.\n\nThey will taste several sweet liquids and tell their preferences.\n\nThey will sit in a bar-like room and be exposed to cues that might make them feel the urge to eat food or drink alcohol.\n\nThey will wear a virtual reality headset that creates a cafeteria setting. They will walk the virtual cafeteria and choose food and drinks from a buffet.\n\nThey will have a functional magnetic resonance imaging (fMRI) scan to take pictures of their brain. During the scans, participants will be shown pictures of alcohol-containing drinks, food, and other items.They will perform tasks on a computer screen.\n\nParticipants will have a follow-up visit about 7 weeks after their last shot.",[28,29],"Addiction","Alcohol Use Disorder",[31,32,33,34],"Alcohol","Pharmacotherapy","GLP-1","Semaglutide","RECRUITING","2026-07-01",{"date":38,"type":39},"2026-07-02","ACTUAL",{"date":41,"type":39},"2023-10-17",{"date":43,"type":22},"2030-12-31",{"name":45,"class":46},"National Institute on Drug Abuse (NIDA)","NIH",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":47},"100217453","behavioral-and-functional-task-development-implementation-and-testing-100217453","NCT02108054","Behavioral and Functional Task Development, Implementation, and Testing","* INCLUSION CRITERIA:\n* between 18-65 years of age. The PI or designated AI will determine if any of the exclusion criteria listed below applies\\*.\n\nEXCLUSION CRITERIA:\n\n* Are not cleared on a neuromotor examination\n* Are currently receiving psychotropic medication\n* Inpatients only: Currently experiencing symptoms of withdrawal from alcohol (As determined by the most recent measurement within the\n\npast 30 days CIWA score \\> 8).\n\n-MRI Exclusion Criteria:\n\n* Presence of ferromagnetic objects in the body including implanted pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent eye liner or small metallic fragments in the eye that welders and other metal workers may have;\n* Are pregnant, as determined by a negative pregnancy test\n* Left handed\n* Claustrophobia.\n\n  * To minimize discomfort and undue burden on the participants, unless available from phone screening, pre-screening, or other NIAAA studies such as 14-AA-0080, 14-AA-0181, we collect the above information as part of this study.",true,"65 Years",{"count":57,"type":22},400,[59],"NA","Background:\n\n\\- Scientists know that alcohol use disorders affect brain structure. They want to know more about the effects of alcohol use disorders on a person s behavior. They want to develop tasks that can be done inside a scanner that can help them better understand these effects in later studies.\n\nObjective:\n\n\\- To develop tasks that investigate a person s behavior that can be used in later studies.\n\nEligibility:\n\n* Inpatient participants of another study. They must be physically healthy right-handed adults 18-60 years old.\n* Healthy right-handed volunteers 18-65 years old.\n\nDesign:\n\n* Participants will be screened with medical history and physical exam. They will have an EKG to record heart activity. They will give blood and urine samples and have a psychiatric interview.\n* Participants will have between one and three visits.\n* Participants will be asked about their alcohol drinking to see if they have an alcohol use disorder.\n* Participants will complete one of three simple computerized tasks either inside the magnetic resonance imagining (MRI) scanner or outside of it.\n* The MRI scanner takes pictures of the brain. The scanner is a metal cylinder. Participants lie on a table that can slide in and out of the cylinder. They will be in the scanner for about 60 minutes. They may have to lie still for up to 20 minutes. The scanner makes loud knocking noises, but they will get earplugs.",[62,63,64,29,28],"Alcohol Dependence","Alcohol Drinking","Alcoholism",[66,64,67,68,69,70,71],"fMRI","Phenotype","Imaging","EEG","Psychophysiology","Near Infrared","2026-06-27",{"date":74,"type":39},"2026-06-30",{"date":76,"type":39},"2014-05-28",{"date":78,"type":22},"2026-12-31",{"name":80,"class":46},"National Institute on Alcohol Abuse and Alcoholism (NIAAA)",{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":54,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":102,"locationsCount":47},"100637303","phase-1-comparative-evaluation-of-nicotine-analogs-100637303","NCT07585006","Comparative Evaluation of Nicotine Analogs","CENA","Inclusion Criteria:\n\n* Aged 21 years or older\n* Current adult EC user for at least the past 3 months (confirmed by cotinine testing strip)\n* Willing and able to provide informed consent\n* Willing to abstain from using any nicotine, tobacco, or marijuana products for 12 or more hours prior to the three lab visits\n* Able to read, write, and speak English\n\nExclusion Criteria:\n\n* Currently attempting to quit nicotine or tobacco products\n* Use of other tobacco or nicotine products \\> 10 days in the past month\n* Have had a recent cardiac event or distress (defined as occurring within the previous 3 months)\n* Have had a recent serious lung disease or infection (e.g., tuberculosis, cystic fibrosis, asthma, or lung cancer) (defined as occurring in the previous 30 days)\n* Currently pregnant, planning to become pregnant, or breastfeeding (verified with urine pregnancy test)","21 Years",{"count":90,"type":22},70,[92],"PHASE1","This phase I trial compares electronic cigarette (EC) user preferences and smoking behaviors of nicotine analogs to nicotine to improve the understanding of nicotine analog addictiveness. Over the last ten years, EC use has become a major concern due to its increased use among adolescents and young adults. Though progress has been made in regulating nicotine containing products, some companies have shifted toward producing products containing nicotine analogs. ECs are battery-powered electronic devices designed to atomize a nicotine (the poisonous chemical found in tobacco)-containing liquid solution for inhalation in a manner that simulates smoking a tobacco cigarette. When nicotine enters the body, it causes an increased heart rate and use of oxygen by the heart, and a sense of well-being and relaxation. Nicotine analogs are compounds that are similar to nicotine in their chemical structure. Some nicotine analogs have been shown to have nicotine-like effects; however, more research is needed to prove they function similarly to nicotine and\u002For have similar effects. Comparing EC user preferences and smoking behaviors of nicotine analogs to nicotine may help improve the understanding of nicotine analog addictiveness.\n\nAdditionally, combustible cigarette smoking is well-known to have deleterious effects on cardiovascular health. High blood pressure is one of the major health consequences of cigarette smoking and can increase the risk of hypertension, heart attack, and stroke. Although ECs have been marketed as a less harmful alternative to cigarette smoking, clinical trials have shown that vaping ECs can also lead to acute increases in blood pressure and heart rate. Nicotine can alter vascular reactivity by promoting the release of vasoconstrictors and suppressing the production of vasodilators. No research has examined how the synthetic nicotine in ECs affects hemodynamics, vascular health, and endothelial function. Assessing acute cardiovascular responses to nicotine analogs is therefore critical to enhancing our understanding of the potential cardiovascular risks associated with vaping ECs containing synthetic nicotine.",[95,28],"Tobacco-Related Carcinoma","2026-06-23",{"date":98,"type":39},"2026-06-26",{"date":100,"type":39},"2026-05-29",{"date":78,"type":22},{"name":103,"class":104},"Ohio State University Comprehensive Cancer Center","OTHER",{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":54,"sex":17,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":125,"locationsCount":47},"100643904","mobile-restriction-on-dopamine-transporter-100643904","NCT07663474","Mobile Restriction on Dopamine Transporter","Inclusion Criteria:\n\n* Healthy subjects with daily use of mobile phone (IPhone)\n* Accessible with \"Screentime\" application\n\nExclusion Criteria:\n\n* Neuropsychiatric disease\n* Subjects who have medications for mental illness\n* Subjects who cannot undergo PET scans\n* Subjects who cannot participate 4 weeks of this study","19 Years","40 Years",{"count":114,"type":22},30,[59],"Restriction of mobile phone use for 2wks and undergo PET scanning for DAT bindinng. Free use of mobile phone use for 2wks and undergo PET scanning for DAT bindinng.",[28,118],"SMARTPHONE OWNER","2026-06-22",{"date":121,"type":39},"2026-06-25",{"date":123,"type":39},"2026-05-01",{"date":43,"type":22},{"name":126,"class":104},"Pusan National University Hospital",{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":17,"minAge":135,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":139,"conditions":140,"keywords":166,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":47},"100619125","neuroimaging-of-adolescent-cannabis-use-treatment-100619125","NCT07340554","Neuroimaging of Adolescent Cannabis Use Treatment","Neuroimaging of Instrumental Learning Networks in Adolescent Cannabis Use Treatment","ACT","Inclusion Criteria:\n\n* 14-17 year old youth\n* Guardian 18 years or older\n* Youth is MRI-eligible: No metal implants, prosthetics, orthodontic devices, transdermal medication patches, piercings and\u002For hair or eyelash extensions that cannot easily be removed, metallic ink tattoos on the neck or face, or claustrophobia, and are not pregnant\n* Youth must endorse having used cannabis at least once per week over the past month OR youth must have been diagnosed with cannabis use disorder within the past three months\n\nExclusion Criteria:\n\n* Youth has a history of Fetal Alcohol Spectrum Disorder, intellectual disorders, pervasive development disorder or autism spectrum disorder, psychotic disorders, history of neurological problems (epilepsy, traumatic brain injury, brain tumor, cerebrovascular disease) by parent\u002Fguardian report\n* Youth or caretaker who is monolingual non-English speaker\n* Youth who is currently experiencing active psychosis symptoms or suicidal\u002Fhomicidal ideation or who has been hospitalized within the past 6 months for psychosis or suicidality\u002Fhomicidality\n* Youth who is currently undergoing contingency management treatment for cannabis use disorder","14 Years","17 Years",{"count":21,"type":22},[59],"This study is testing whether brain activity related to learning can help predict how well teens respond to a treatment program designed to reduce cannabis use. Teens ages 14-17 will complete a brain scan and then take part in 10 weekly virtual sessions where they report cannabis use and complete drug tests at home. Participants can earn prizes for staying cannabis-free.",[141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,28,159,160,161,162,163,164,165],"Cannabis Use","Cannabis Dependence","Cannabis Use Disorder","Cannabis Abuse","Cannabis Intoxication","Cannabis Smoking","Cannabis Withdrawal","Cannabis-Related Disorder","Cannabis Abuse, in Remission","Cannabis Abuse, Episodic Use","Marijuana","Marijuana Abuse","Marijuana Use","Marijuana Smoking","Marijuana Dependence","Marijuana User","Marijuana-Related Disorder","Marijuana Use Disorder","Addiction, Substance","Substance Use","Substance Use Disorders","Substance Dependence","Substance Abuse","Substance Related Problem","Substance Abuse Drug Chronic",[167,151,28],"Cannabis","2026-06-18",{"date":119,"type":39},{"date":171,"type":39},"2026-06-15",{"date":173,"type":22},"2030-05-01",{"name":175,"class":104},"Indiana University",{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":23,"phases":186,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":47},"100563637","motivational-interviews-post-hospitalisation-on-maintaining-abstinence-for-1-year-aprs-le-sevrage-en-alcool-100563637","NCT06618755","Motivational Interviews Post Hospitalisation on Maintaining AbstiNence for 1 Year après le Sevrage en Alcool","IMMANENCE - Intérêt d'un Suivi Sous Forme d'Entretiens Motivationnels spécifiques Post Hospitalisation Sur le Maintien de l'AbstiNENCE Durant l'année Suivant le Sevrage en Alcool","IMMANENCE","Inclusion Criteria:\n\n* With alcohol use disorders defined by at least 2 DSM-V criteria for at least 12 months).\n* Being treated for withdrawal in hospital.\n* With a goal of complete abstinence.\n* With a means of communication (telephone).\n\nExclusion Criteria:\n\n* Lack of understanding (written and spoken) of the French language.\n* Breach of HC withdrawal contract, following failure to comply with the rules of the addictology service and somatic complications of addiction.\n* Eviction from the department, discharge against medical advice during hospitalisation for withdrawal.\n* Proven cognitive problems compromising understanding of the implications of the study and the proposed follow-up. proposed follow-up.\n* Serious decompensated somatic pathology.\n* Non-membership or non-beneficiaries of a national health insurance scheme.\n* Person protected by law, under guardianship or curatorship.\n* Not having signed free and informed consent to participate in the research.\n* Simultaneous participation in another clinical trial.",{"count":185,"type":22},104,[59],"The aim of this clinical study is to evaluate the efficacy of reinforced inpatient aftercare versus usual care on the percentage of days of abstinence during the first year following withdrawal in adults with alcohol use disorders undergoing inpatient withdrawal. The hypothesis is that reinforced post-withdrawal follow-up, of the motivational interview type, during the first 4 months following hospitalisation, in addition to the usual care, would allow :\n\n* Increase the percentage of days of abstinence in the year following withdrawal.\n* Reduce the rate of relapse in the year following withdrawal.\n* An increase in the cumulative and maximum duration of abstinence, an increase in motivation to maintain the change initiated and a reduction in the use of other substances in the year following withdrawal.\n* A reduction in the impact of risk factors involved in the relapse process in the year following withdrawal.\n\nAll participants will have assessments to monitor their abstinence and consumption. In addition to their assessments, the experimental group will have motivational talks once every 15 days.",[29,28,189,190,191],"Alcohol Withdrawal","Motivational Interviews","Relapse","2026-06-17",{"date":168,"type":39},{"date":195,"type":39},"2024-12-18",{"date":197,"type":22},"2028-01-13",{"name":199,"class":104},"University Hospital, Montpellier",{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":210,"phases":4,"briefSummary":211,"conditions":212,"keywords":213,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":222,"leadSponsor":224,"locationsCount":47},"100637027","pain-and-upper-extremity-function-in-smartphone-and-digital-game-addiction-100637027","NCT07573345","Pain and Upper Extremity Function in Smartphone and Digital Game Addiction","The Effects of Smartphone and Digital Game Addiction on Pain and Upper Extremity Function: A Comparative Study","Inclusion Criteria:\n\n* Being between 18-45 years old\n* Volunteering to participate in the study\n\nExclusion Criteria:\n\n* Individuals who have undergone major surgery or trauma related to the musculoskeletal system, primarily the upper extremities and trunk\n* Individuals with neurological diseases\n* Individuals with active rheumatic diseases\n* Individuals with systemic diseases (diabetes, hypothyroidism, infection, malignancy, etc.)\n* Individuals with serious psychological problems (scoring 30 or higher on the BDE)\n* Individuals with contraindications to the assessment methods (acute inflammations, viral and bacterial infections, infectious diseases, fever, deep vein thrombosis, active malignant disease, aneurysms)\n* Obesity (BMI ≥ 30 kg\u002Fm2)","45 Years",{"count":209,"type":22},60,"OBSERVATIONAL","With the expansion of technology-based applications, daily phone use has increased significantly. According to a 2020 study, phone use habits among young adults aged 18-34 increased by 38.1%, and the time spent on the phone exceeding one hour increased by 68%. Currently, there is no clear definition of smartphone \"addiction\" or smartphone use, but like other types of addiction, it refers to the effort to control smartphone habits that cause problems or distress in daily life. Recent studies have reported a correlation between excessive screen use and individuals' mental and physical health. Excessive use of phones and video games causes many negative effects, including attention deficit, inability to enjoy life, hyperactivity, depression, anxiety, pain, and functional loss.\n\nVideo games are a type of game played through an audiovisual device and can be story-based. While many video games improve players' critical thinking, strategic planning, and problem-solving skills, they can also cause musculoskeletal problems due to the long hours spent at the desk and the repetitive movements involved.\n\nThe human spine is a kinematic chain with all joints interconnected; this means that changes in other body parts, such as the increased head tilt while texting on a smartphone, can have significant effects on the entire spine. A 2023 study showed an increase in spinal curvature, particularly in the cervical region, as smartphone use time increased. A study in Korea linked smartphone use to increased pain in the neck, wrists, hands, shoulders, and back. Another significant problem for smartphone users and video game players is \"text neck,\" which occurs from prolonged screen time. This causes tension in the cervical spine, leading to neck pain and stiffness.\n\nSmartphone addiction leads to hand-related problems, primarily hand and wrist pain. Furthermore, excessive use of smartphones, game controllers, and joysticks can lead to repetitive strain injuries such as carpal tunnel syndrome. Prolonged phone use, repetitive movements, and uncomfortable hand positions during use cause inflammation of the muscles and tendons in the hands and wrists, leading to swelling, pain, and loss of function in these joints. Video games are played using devices such as computers, consoles, handheld computers, and smartphones. The continuous, repetitive, and uninterrupted movements performed while using these devices can lead to musculoskeletal disorders, particularly in the upper extremities. Prolonged playing of these games results in musculoskeletal problems such as carpal tunnel syndrome and tendinitis. Extensive studies have shown that individuals' pain and symptoms worsen after prolonged gaming sessions. However, to date, there has been no study comparing smartphone addicts and video game players.\n\nThe aim of this research is to compare individuals with smartphone addiction, those who play video games for extended periods, and those without these habits in terms of pain, posture, and upper extremity function.",[28],[214,215,216,217],"upper extremity performance","Pain","Smartphone","Game","2026-05-24",{"date":220,"type":39},"2026-05-27",{"date":123,"type":39},{"date":223,"type":22},"2026-07-15",{"name":225,"class":104},"Istinye University",{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":232,"enrollmentInfo":233,"targetDuration":4,"studyType":23,"phases":235,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":238,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":4},"100639115","support-towards-addiction-recovery-for-individuals-with-criminal-legal-system-involvement-the-star-project-100639115","NCT07596251","Support Towards Addiction Recovery for Individuals With Criminal Legal System Involvement: The STAR Project","Inclusion Criteria:\n\n* Recovering Persons:\n* At least 18 years old\n* Must have been involved with the criminal legal system (arrested, incarcerated, or on community supervision like parole or probation) within the past 12 months\n* Substance use disorder within the past 12 months\n* Interested in working with a recovery coach to support your recovery (defined as engaging in any changes to improve your health and wellness)\n* Can identify at least one person who is supportive of their recovery.\n* Loved Ones:\n* At least 18 years old\n* Interested in receiving additional supports and\u002For information about their loved one's substance use and criminal legal system involvement\n* Anticipate being available for weekly participation in intervention activities\n* Willing to support their loved one's recovery\n\nExclusion Criteria:\n\n* Loved ones:\n* Already have a professional relationship with the recovering person (e.g., as a counselor, sponsor, or peer recovery support specialist)\n* Meet substance use disorder criteria for any past 30-day drug or alcohol use\n* Have a history of domestic violence or protective orders.","99 Years",{"count":234,"type":22},8,[59],"The goal of this clinical trial is to determine whether a new, paired coaching intervention improves outcomes for individuals with criminal legal system involvement recovering from substance use disorder, as well as the loved ones of those individuals. The initial phase (Year 1) includes a small preliminary pilot examining the feasibility of the intervention.\n\nDuring the full clinical trial (Years 2-5), this study aims to answer whether this approach...\n\n* ...improves the recovering person's recovery capital?\n* ...improves well-being, as well as resource knowledge and awareness, for the loved one?\n* ...improves social support and connection among both individuals?\n\nParticipants will:\n\n* Meet regularly one-on-one with their individual coaches (a Recovery Coach for the recovering person; a Loved One Coach for the loved one) during the 6 week intervention period\n* Meet regularly as a group of four (both coaches and both participants) during this same period\n* Complete follow-up interviews with research staff at 6- and 12-weeks after beginning the study",[28],"NOT_YET_RECRUITING","2026-05-22",{"date":241,"type":39},"2026-05-28",{"date":243,"type":22},"2026-09-01",{"date":245,"type":22},"2031-03-01",{"name":247,"class":104},"Martha Tillson",{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":12,"sex":256,"minAge":18,"maxAge":4,"enrollmentInfo":257,"targetDuration":259,"studyType":210,"phases":4,"briefSummary":260,"conditions":261,"keywords":266,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":47},"100637591","nlp-analysis-of-weekly-narratives-for-dynamic-clinical-assessment-in-sud-100637591","NCT07595614","NLP Analysis of Weekly Narratives for Dynamic Clinical Assessment in SUD","Analysis of Weekly Narratives Using Natural Language Processing in Patients Undergoing Residential Rehabilitation: A Hybrid Approach for the Dynamic Assessment of Clinical Processes","DYNA-NLP","Inclusion Criteria:\n\n1. Clinical diagnosis of severe substance use disorder (polydrug use, including cocaine, methamphetamines, alcohol, and\u002For cannabis), confirmed by the center's admission assessment.\n2. Male sex (all participants in the center's residential program are male).\n3. Age 18 years or older.\n4. Current resident of the participating residential rehabilitation center in Mexico.\n5. Completed at least four weeks of residential treatment at the time of study enrollment.\n6. Able to write coherent weekly narratives in Spanish (no severe cognitive impairment or active psychosis).\n7. Willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Presence of acute psychotic symptoms that interfere with the ability to write or understand the study procedures.\n2. Severe cognitive impairment (e.g., due to traumatic brain injury, intellectual disability) that prevents meaningful narrative production.\n3. Inability to comply with weekly narrative writing (e.g., illiteracy, severe visual impairment).\n4. Planned discharge from the residential program within less than 4 weeks from enrollment.\n5. Enrollment in another interventional clinical trial that could confound the interpretation of outcomes.","MALE",{"count":258,"type":22},35,"20 Weeks","This prospective observational study follows adults undergoing residential rehabilitation for severe substance use disorders at a specialized treatment center in Mexico. Participants provide weekly written narratives describing their emotions, challenges, coping strategies, and treatment experiences, and complete validated psychological questionnaires every two weeks, including the Generalized Anxiety Disorder-7 (GAD-7), Environmental Reward Observation Scale (EROS), Automatic Thoughts Questionnaire-8 (ATQ-8), and Behavioral Activation for Depression Scale (BADS).\n\nThe study applies natural language processing (NLP) and machine learning methods to analyze participants' narratives and identify emotional, cognitive, and behavioral patterns associated with clinical change over time. Narrative-derived features are combined with questionnaire scores to generate a dynamic clinical risk representation that may help detect early signs of psychological worsening or improvement during residential treatment.\n\nParticipants continue receiving standard residential care, and the study does not modify treatment decisions or clinical interventions. Up to 35 participants with sufficient longitudinal follow-up data will be included in the primary analysis. Data collection is expected to continue through September 2026.",[262,28,263,264,265],"Substance Use Disorder (SUD)","Anxiety","Emotional Dysregulation","Rumination - Thoughts",[267,268,269,270,271],"Natural Language Processing","Machine Learning","Behavioral Activation","Automatic Thoughts","Residential Rehabilitation","2026-05-14",{"date":274,"type":39},"2026-05-19",{"date":276,"type":39},"2025-05-25",{"date":278,"type":22},"2026-09",{"name":280,"class":104},"Lauro Gutiérrez Castro",{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":17,"minAge":288,"maxAge":55,"enrollmentInfo":289,"targetDuration":4,"studyType":23,"phases":291,"briefSummary":292,"conditions":293,"keywords":294,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":47},"100590906","habits-study-helping-addiction-by-individualized-therapeutic-stimulation-pilot-trial-of-deep-brain-stimulation-guided-by-stereoelectroencephalography-for-treatment-refractory-substance-use-disorders-100590906","NCT06973512","HABITS Study (Helping Addiction by Individualized Therapeutic Stimulation): Pilot Trial of Deep Brain Stimulation Guided By Stereoelectroencephalography for Treatment-Refractory Substance Use Disorders","HABITS","Inclusion Criteria:\n\n* Adult, Age 25-65\n* Severe DSM-5 substance use disorder (SUD) as assessed by Structured Clinical Interview for DSM-5 (SCID-5)\n* Treatment refractory as evidenced by non-response to an adequate trial of ≥2 evidence-based treatment modalities for their substance use disorder in the most recent 3 years of illness, as determined by the study clinical team\n* Able to comply with study visit schedule and timeline\n* Stable housing and reliable transportation\n* Treatment-seeking (\\>7 on a 0-10 readiness ruler and open to the end-of-treatment outcome of abstinence)\n* Capable of understanding and providing informed consent\n\nExclusion Criteria:\n\n* Contraindications to neurosurgical interventions such as major medical co-morbidities, including uncontrolled hypertension, coagulopathy, severe diabetes, major organ system failure, active infection or history of implant-related infections, immunocompromised state, or malignancy with \\\u003C5 years life expectancy\n* Contraindications for MRI, including implanted metallic devices (e.g., non-MRI-safe cardiac pacemaker or neurostimulator; some artificial joints metal pins; surgical clips; or other implanted metal parts), or claustrophobia or discomfort in confined spaces\n* Cardiac pacemaker\u002Fdefibrillator, or other implanted stimulator\n* Presence of epilepsy, stroke, or degenerative disorder of the nervous system\n* Serious problems with literacy, vision, or hearing","25 Years",{"count":290,"type":22},10,[59],"Substance use disorder (SUD) or addiction to drugs\u002Falcohol is a devastating disease. Over 40,000 overdose deaths have happened in Canada since 2016, 1 in 5 Canadians will have a SUD, and 70% of those with SUD continue to relapse, showing that we urgently need new treatments. The Helping Addiction by Individualized Therapeutic Stimulation (HABITS) Study is exploring deep brain stimulation (DBS) for people who have failed to quit harmful substances.\n\nOver 250,000 people have received DBS, which is well-established for Parkinson's disease and has evidence of success in major depression and obsessive-compulsive disorder. DBS uses electricity to directly stimulate areas of the brain. However, for DBS to work effectively, it needs to be personalized to each individual, which will be pursued through stereoelectroencephalography (SEEG). DBS and SEEG are minimally invasive and reversible, with a low risk of side effects.\n\nSEEG started over 70 years ago to find seizure location in the brain of children and adults with epilepsy. It now has been used for major depression and chronic pain to guide DBS. It involves inserting electrodes temporarily across critical brain areas and monitoring patients for several days. SEEG can provide an understanding of where addiction and craving are in the brain to guide the placement of DBS electrodes and device settings that are optimal for a person.\n\nIn the HABITS Study, 10 participants will receive DBS guided by SEEG and undergo 11 study visits. Individuals will first undergo detoxification with CAMH. Then, they will receive DBS and SEEG at Toronto Western Hospital, where they will stay for 1 to 2 weeks. Finally, they will be followed for a year, where they will receive standard psychiatric care.\n\nSUD causes heavy burdens on individuals, families, healthcare systems, and society. The HABITS Study promises to personalize DBS to treat those who are struggling with severe addiction.",[28,262],[295,296,297,298,299,300],"addiction","substance use disorder","deep brain stimulation","stereoelectroencephalography","biomarker","electrophysiology","2026-04-27",{"date":303,"type":39},"2026-04-29",{"date":305,"type":39},"2024-11-01",{"date":307,"type":22},"2028-01-01",{"name":309,"class":104},"Centre for Addiction and Mental Health",{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":317,"targetDuration":4,"studyType":210,"phases":4,"briefSummary":319,"conditions":320,"keywords":331,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":343,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":350},"100564051","computer-game-qualitative-and-megeeg-assessment-of-serotonergic-psychedelics-100564051","NCT06624137","Computer Game, Qualitative, and MEG\u002FEEG Assessment of Serotonergic Psychedelics","Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects","Inclusion Criteria:\n\n* Participation in approved clinical protocol at Yale University involving potential administration of serotonergic psychedelics\n* Absence of pre-existing psychotic symptoms\n\nExclusion Criteria:\n\n* Current intoxication based on self-report\n* Any neurological, medical or developmental problem that is known to impair cognition significantly based on self-report\n* History of seizures based on self-report\n* Contraindications for MR scanning including metallic implants of any kind, pacemakers and history of accidents with metal, claustrophobia (specific to those who will participate in MRI)",{"count":318,"type":22},200,"This is an observational study which does NOT directly administer a psychedelic substance but rather recruits participants who are already participating in another clinical trial in which they may receive a serotonergic psychedelic. The goal of this observational study is to learn how the brain's information processing changes during and following administration of serotonergic psychedelics (psilocybin, N,N-Dimethyltryptamine\u002FDMT, Lystergic Acid Diethylamide\u002FLSD, etc.) for people with and without mental illness receiving serotonergic psychedelics through any clinical trial at Yale University. The main questions it aims to answer are:\n\n1. Do serotonergic psychedelics cause the brain to rely on new information more than previously learned information while under the influence? What about 1 day, 5-14 days, and 4-6 weeks after use?\n2. Do serotonergic psychedelics cause long-lasting side-effects in how people perceive (see, hear, feel, etc.) the world and how easily people change their beliefs?\n3. How does the brain's electrical activity change after using serotonergic psychedelics? How does the balance between excitation and inhibition change while under their effect?\n4. Can changes in how the brain uses information predict who will benefit from a psychedelic and who will have side effects from psychedelics?\n\nResearchers will compare with people given placebos to see what changes in brain processing are unique to serotonergic psychedelics.\n\nParticipants will have the opportunity to do some combination of the following:\n\n1. Online computer assessments consisting of games and questionnaires that probe how participants think.\n2. Magnetoencephalography (MEG) or electroencephalography (EEG) with eyes closed and with repeated clicks, images, or sensations delivered.\n3. A magnetic resonance imaging (MRI) scan.\n4. Semi-structured qualitative interviews about their experience after taking a serotonergic psychedelic recorded via Zoom.",[321,322,323,324,325,326,327,28,328,329,330],"OCD","Major Depressive Disorder (MDD)","Alcohol Use Disorder (AUD)","Healthy Volunteer","Migraine","PTSD","PTSD - Post Traumatic Stress Disorder","Tobacco Use Disorder","Obsessive Compulsive Disorder (OCD)","Opioid Use Disorder",[332,333,334,335,336,337,338,339,340,341,342],"Psilocybin","DMT","N,N-dimethyltryptamine","Ayahuasca","Lysergic acid diethylamide","LSD","5-MeO-DMT","O-methyl-bufotenin","eeg","meg","5-Methoxy-N,N-Dimethyltryptamine",{"date":123,"type":39},{"date":345,"type":39},"2024-12-12",{"date":347,"type":22},"2028-05",{"name":349,"class":104},"Yale University",2,{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":17,"minAge":359,"maxAge":360,"enrollmentInfo":361,"targetDuration":4,"studyType":23,"phases":363,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":238,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":47},"100632971","evaluation-of-the-addpro-vocational-reintegration-program-add-pro-eval-100632971","NCT07520617","Evaluation of the ADD'Pro Vocational Reintegration Program (ADD-PRO-EVAL)","Evaluation of the ADD'Pro Program: A Partnership-Based Approach to Support Vocational Reintegration of Patients Receiving Addiction Care (ADD-PRO-EVAL)","ADD-PRO-EVAL","Inclusion Criteria:\n\n* Adult of working age (18 years or older)\n* Diagnosed substance use disorder receiving medical care\n* Unemployed or on sick leave with a vocational reorientation project\n* Motivated to work in the competitive labour market\n* Living in or wishing to work in the Puy-de-Dôme department (63), France\n* Legally authorised to work\n* Capable of providing written informed consent\n* Affiliated with a French social security scheme\n\nExclusion Criteria:\n\n* Medical care provided under a court-ordered treatment obligation\n* Previously included in the ADD'Pro program\n* Residing outside the Puy-de-Dôme with no plan to work in the department\n* Under legal guardianship (tutelle, curatelle, or sauvegarde de justice)\n* Deprived of liberty","16 Years","70 Years",{"count":362,"type":22},100,[59],"The goal of this clinical trial is to evaluate whether an integrated medico-psychosocial vocational support program (ADD'Pro) can improve employment outcomes in adults with substance use disorders receiving care at a specialized addiction day hospital.\n\nThe main question it aims to answer is:\n\n\\- Does participation in the ADD'Pro program increase the rate of competitive employment (at least one day worked in the open labour market) at 6 months compared to standard employment services?\n\nResearchers will compare participants enrolled in the ADD'Pro program to participants referred to conventional employment services (France Travail or Cap Emploi) to see if structured, dual medico-psychosocial support leads to higher rates of vocational reintegration, better employment preparation, improved quality of life, and reduced physiological stress reactivity.\n\nParticipants will:\n\n* Be randomly assigned to either the ADD'Pro program or standard employment services\n* If assigned to ADD'Pro: receive immediate individualised support from a vocational counsellor (CIP) at the CeCler Association, running in parallel with their hospital addiction care, with no fixed end date\n* If assigned to standard care: be referred to conventional employment services with monthly follow-up interviews at the hospital, and the option to join ADD'Pro after 6 months\n* Complete structured interviews and validated questionnaires at inclusion, 3, 6, and 12 months\n* A sub-sample of up to 50 participants will additionally take part in a simulated job interview stress test (adapted TSST) with salivary biomarker collection and heart rate monitoring at inclusion and 6 months",[28,366,367,368,369,370,262,371,372,373,374,375],"Addiction Disorders","Substance Use Recovery","Return to Work","Recovery","Recovery Outcomes","Employment, Supported","Employment","Substance Related Disorders","Vocational Rehabilitation","Substance Use (Drugs, Alcohol)","2026-04-02",{"date":378,"type":39},"2026-04-09",{"date":380,"type":22},"2026-04",{"date":382,"type":22},"2029-04",{"name":384,"class":104},"University Hospital, Clermont-Ferrand",{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":23,"phases":394,"briefSummary":395,"conditions":396,"keywords":401,"overallStatus":238,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":409,"leadSponsor":411,"locationsCount":4},"100631066","the-impact-of-equine-assisted-therapy-on-mental-health-and-addictive-behaviors-in-patients-receiving-addiction-treatment-100631066","NCT07495839","The Impact of Equine-Assisted Therapy on Mental Health and Addictive Behaviors in Patients Receiving Addiction Treatment","EQUI-ADDICT","Inclusion Criteria:\n\n* Adult patients over the age of 18,\n* Patients who have completed detoxification and have been hospitalized at least once in the nutrition and alcoholism unit at La Musse Hospital or at another facility,\n* Patients with an addiction to a psychoactive substance (e.g., alcohol, tobacco, cannabis),\n* Able to participate in animal-assisted therapy sessions,\n* Ability to understand instructions during sessions,\n* Enrolled in the social security system.\n\nExclusion Criteria:\n\n* Patients with a behavioral addiction not involving substances (e.g., gambling, sexual addiction),\n* Patients who have not yet completed detoxification,\n* Patients under legal guardianship,\n* Patients currently undergoing other animal-assisted therapy,\n* Allergies to horses,\n* Other serious medical conditions that may interfere with participation in the sessions.",{"count":393,"type":22},22,[59],"Addiction is a major public health issue. According to the World Health Organization (2024), approximately 400 million people worldwide suffer from alcohol- or drug-related disorders, resulting in nearly 3.2 million deaths per year. In France, the situation is also cause for concern: approximately three million people engage in risky alcohol consumption, thirteen million smoke daily, and nearly one and a half million use illicit drugs, primarily cannabis.\n\nAddiction, defined by the National Institute on Drug Abuse (NIDA) as a chronic, relapsing brain disorder, is characterized by the compulsive pursuit and use of a substance despite knowledge of its harmful effects. Its development depends on multiple factors: personal (trauma, psychiatric disorders, genetic predispositions), environmental (stress, isolation, family context), and those related to the substance itself (addictive potential). The diagnosis of substance use disorders is based on 11 criteria defined in the \\*Diagnostic and Statistical Manual of Mental Disorders\\* (DSM-5), the main ones being: loss of self-control, interference of substance use with academic or occupational activities, continued use despite awareness of the problems it causes, and a new central criterion, craving, defined as an irresistible urge to use, which serves as both a symptom and a diagnostic and prognostic marker because it is a predictor of relapse. The cumulative total of criteria allows the disorder to be classified as mild (2-3), moderate (4-5), or severe (≤ 6). Since the 2020 health crisis, researchers have observed an increase in the use of psychoactive substances, particularly among vulnerable populations. Despite public policy efforts and treatment programs, relapses remain common after treatment, affecting 60 to 70% of patients within six months of their hospitalization. This phenomenon is also observed at La Musse Hospital, where many patients admitted to the nutrition and alcoholism unit express a sense of emptiness upon returning home: a void in relationships, therapy, and daily activities. This feeling often contributes to a return to substance use.\n\nTo address these relapses, this study aims to evaluate the impact of a post-hospitalization equine-assisted therapy program on the mental health and addictive behaviors of patients receiving addiction treatment. Already used at La Musse Hospital as part of the care pathway, equine-assisted therapy is based on the interaction between the patient and the horse in a therapeutic setting. Several studies have demonstrated the benefits of this approach on emotional regulation, self-confidence, stress management, and overall well-being.\n\nThis prospective, single-center, interventional study will include twenty-two patients who have been hospitalized at least once in the nutrition and alcoholism unit at La Musse Hospital or another facility. Participants will be randomly assigned to either a group receiving post-hospitalization equine-assisted therapy or a control group.",[397,28,398,399,400],"Equine-assisted Therapy","Recidivism","Addictive Behaviors","Mental Health",[402,28,398,403,404],"Equine mediation","Addictive behavior","Mental health","2026-03-26",{"date":407,"type":39},"2026-04-01",{"date":407,"type":22},{"date":410,"type":22},"2028-08-31",{"name":412,"class":104},"Hopital La Musse",{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":420,"targetDuration":4,"studyType":23,"phases":422,"briefSummary":423,"conditions":424,"keywords":427,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":47},"100584151","the-use-of-tdcs-for-vaping-reduction-100584151","NCT06885606","The Use of tDCS for Vaping Reduction","Using Transcranial Direct Current Stimulation (tDCS) for Vaping Reduction in Daily E-cigarette Users: a Pilot Study","Inclusion Criteria:\n\n* The participant must meet all of the inclusion criteria to be eligible for this research study:\n\n  1. Be able to provide informed written consent\n  2. Stated willingness to comply with all study procedures\n  3. Age 18 - 65 years\n  4. Is a daily regular use of nicotine-containing e-cigarette for at least the past 6 months\n  5. Is willing to attend daily appointments for tDCS for two consecutive weeks (Monday through Friday)\n  6. Is not interested in or planning to quit vaping in the next 30 days.\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this research study:\n\n  1. Substance use disorder (other than nicotine dependence) (M.I.N.I. SCID) (confirmed with urine drug screen)\n  2. Current regular use of tobacco cigarettes, nicotine replacement therapy or other medications for smoking cessation\n  3. Unstable psychiatric condition\n  4. Recent clinically significant head trauma\\*\n  5. History of seizures and\u002For epilepsy\\*\n  6. Pacemakers or implanted electrical devices such as cochlear implants\\*\n  7. Metal embedded in the skull\\*\n  8. Skin lesions, open wounds, bruising, or similar injuries on the scalp\\*",{"count":421,"type":22},40,[59],"Project Summary - tDCS for Vaping Reduction\n\nBackground: While the prevalence of tobacco smoking has plateaued over the last several years, the prevalence of nicotine vaping (e-cigarettes) continues to increase exponentially in Canada. Originally touted as a safe alternative to smoking, e-cigarette use or vaping is now most popular among youth and young adults. The high prevalence of e-cigarette use, coupled with growing evidence of associated harms and reports of addiction and difficulties in quitting reinforces the urgent need to develop and test methods to attenuate e-cigarette craving as a step towards developing approaches to vaping cessation that are brief, inexpensive and effective. Non-invasive brain stimulation techniques have become a popular area of research as a treatment option for substance use disorders with growing evidence of their effectiveness for a variety of addictions. One of these techniques, transcranial direct current stimulation (tDCS), has been shown to decrease cigarette craving and consumption. Thus, the purpose of this pilot study is to evaluate the effectiveness of using tDCS for vaping reduction in e-cigarette users.\n\nMethods: This will be a double-blind sham-controlled randomized trial whereby 40 daily nicotine-containing e-cigarette users will be recruited to undergo 10 consecutive daily sessions of tDCS (Monday to Friday for 2 weeks). Participants will be randomized (1:1) to either sham (0mA) or active tDCS (2mA), with the anode at the left dorsolateral prefrontal cortex (DLPFC) and cathode at the right DLPFC. The primary outcome is vaping frequency (puffs\u002Fday and nicotine pods\u002Fweek) at end of treatment (2 weeks). The secondary outcome will be e-cigarette craving. Participants will be followed-up via the phone at 1 month and 3 months post randomization respectively.\n\nImplication: This will be the first treatment study to target vaping reduction. There are currently no established treatment options for e-cigarette addiction and medications traditionally used for smoking cessation only address withdrawal symptoms and not addiction pathology. Thus, findings from this study may be used to inform future designs of vaping reduction strategies or vaping cessation.",[425,28,426],"Vaping","Transcranial Direct Current Stimulation(tDCS)",[428,425,429,430,431],"E-cigarettes","Brain stimulation","tDCS","Nicotine","2026-03-17",{"date":434,"type":39},"2026-03-19",{"date":436,"type":39},"2026-01-01",{"date":438,"type":22},"2026-05",{"name":309,"class":104},{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":447,"enrollmentInfo":448,"targetDuration":4,"studyType":23,"phases":449,"briefSummary":450,"conditions":451,"keywords":455,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":47},"100576691","phase-2-feasibility-of-long-term-high-dose-stimulant-for-methamphetamine-use-disorder-100576691","NCT06788587","Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder","Exploring Feasibility and Acceptability of Prolonged Administration of High-Dose Stimulants in People With Methamphetamine Use Disorder: An Extension of a Randomized, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Between 18 and 55 years of age at enrollment in the parent ASCME trial;\n2. Diagnosed with a moderate to severe MUD as defined by the DSM-5 criteria;\n3. Enrolled in the parent ASCME trial and completed the study up to and including the end of study visit at Week 20, Day 1;\n4. Interested in avoiding relapse, decreasing methamphetamine use, or abstaining from methamphetamine use;\n5. Presence of ongoing substance use, craving, or significant risk of relapse that according to the study physician, warrants extended treatment for MUD;\n6. If female:\n\n   * Be of non-childbearing potential, defined as (i) postmenopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age); or (ii) documented surgically sterilized (i.e., tubal ligation, hysterectomy, or bilateral oophorectomy); or\n   * Be of childbearing potential, have a negative pregnancy test at screening, and agree to use an acceptable method of birth control throughout the study;\n7. Willing to be randomized to one of 2 study arms and followed for the duration of the trial;\n8. Able to start the study intervention within 28 days after completing the ASCME main trial (study no. CRISM-002);\n9. Able to provide informed consent;\n10. Willing to comply with study procedures;\n11. Able to communicate in English or French\n\nExclusion Criteria:\n\n1. Symptomatic or advanced cardiovascular disease (e.g., advanced arteriosclerosis), moderate hypertension; confirmed current hyperthyroidism; known hypersensitivity or idiosyncrasy to the sympathomimetic amines or glaucoma or any disabling, severe, or unstable medical condition (including electrolyte disturbances) that, in the opinion of the study physician, precludes safe participation or the ability to provide fully informed consent;\n2. Any severe or unstable co-morbid substance use disorder that, in the opinion of the study physician, precludes safe participation in the study;\n3. Participants with Opioid Use Disorder (OUD) who have been on Opioid Agonist Treatment (OAT) for \\\u003C12 weeks, and not yet at stabilization dose, or at stabilization dose \\\u003C4 weeks;\n4. Current or a history of any serious psychiatric disorder (e.g., bipolar disorder, pre-existing psychosis, schizophrenia) that, in the opinion of the study physician, precludes safe participation in the study;\n5. History of a SAE, hypersensitivity or known allergic reaction to LDX-01 or other amphetamine drugs, or hypersensitivity to the sympathomimetic amines;\n6. Pregnant, nursing, or planning to become pregnant during the study period;\n7. Planned extended absence during the study period (e.g., pending legal action, surgery, incarceration, inpatient residential program) in the opinion of the study physician that might prevent completion of the study;\n8. Use of an investigational drug for stimulant use disorder during the 30 days before screening, confirmed via self-report or pharmacy records; excluding the use of study medication in the parent ASCME trial;\n9. Use of prescribed amphetamine-type medication or medication for the treatment of stimulant use disorder (e.g., methylphenidate, modafinil, bupropion, or mirtazapine) in the 4 weeks before screening;\n10. Current or anticipated need for treatment with any medication that may interact with LDX-01 (e.g., monoamine oxidase inhibitors \\[MAOIs\\]) used currently or within the past 14 days and that would preclude study participant at the discretion of the study physician;\n11. ECG measurement (Bazett method for the correction of QT interval) that indicates a prolonged QTc interval (≥460 milliseconds for females and ≥450 milliseconds for males) at screening;\n12. Any SAEs related to the study product in the parent trial phase that, in the opinion of the study physician, precludes safe participation in the extension study;\n13. Any compliance issues related to the study product and\u002For study procedures during the parent trial phase that, in the opinion of the study physician, precludes safe participation in the extension study.","55 Years",{"count":21,"type":22},[25],"Methamphetamine use disorder (MUD) is becoming an increasing public health concern in Canada. While the evidence on the efficacy and safety of prescription psychostimulants for the treatment of MUD is promising, the knowledge on the maintenance therapy using stimulant agonist therapy is scarce and needs further investigation, especially in terms of long-term retention in treatment.\n\nThe goal of this clinical trial is to evaluate the feasibility of a long-term (25 weeks) administration of high-dose stimulant agonist therapy, using Lisdexamfetamine (LDX-01) on top of treatment-as-usual (TAU), in a population of people with moderate to severe MUD, as measured by study retention, treatment retention, treatment adherence and satisfaction compared against a placebo group.\n\nParticipants will be placed randomly into one of two groups:\n\n1. TAU and high-dose LDX-01\n2. TAU and placebo",[452,453,28,163,454],"Methamphetamine Abuse","Methamphetamine-dependence","Methamphetamine Use Disorder",[456,457,458,459,460,461,462],"Substance use disorder","Amphetamines","Methamphetamine","Lisdexamfetamine","Treatment","Agonist therapy","Feasibility","2026-02-19",{"date":465,"type":39},"2026-02-23",{"date":467,"type":39},"2025-07-18",{"date":469,"type":22},"2027-12",{"name":471,"class":104},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":447,"enrollmentInfo":479,"targetDuration":4,"studyType":23,"phases":481,"briefSummary":482,"conditions":483,"keywords":484,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":495},"100504925","phase-2-clinical-trial-of-high-dose-lisdexamfetamine-and-contingency-management-in-ma-users-100504925","NCT05854667","Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users","Addition of High Dose Stimulant and Engagement-focused Contingency Management (CM), Alone and in Combination, to Treatment as Usual (TAU) for the Management of Methamphetamine (MA) Use Disorder (ASCME): a Canadian Multi-centre, RCT","Inclusion Criteria:\n\n* Participant must meet all the following criteria:\n\n  1. Between 18 and 55 years of age;\n  2. Diagnosed with a moderate to severe methamphetamine (MA) use disorder as defined by the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) criteria;\n  3. Active MA use at screening measured via self-reported MA use ≥14 days in the past 28 days AND verified by urine drug metabolite testing;\n  4. Interested in reducing\u002Fstopping MA use;\n  5. If female:\n\n     1. Be of non-childbearing potential, defined as (i) postmenopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age); or (ii) documented surgically sterilized (i.e., tubal ligation, hysterectomy, or bilateral oophorectomy); or\n     2. Be of childbearing potential, have a negative pregnancy test at screening, and agree to use an acceptable method of birth control throughout the study;\n  6. Willing to be randomized to one of the 4 study arms and followed for the duration of the trial;\n  7. Able to provide informed consent;\n  8. Willing to comply with study procedures;\n  9. Able to communicate in English or French.\n\nExclusion Criteria:\n\n* 1\\. Symptomatic or advanced cardiovascular disease (e.g., advanced arteriosclerosis), moderate hypertension; current hyperthyroidism confirmed via blood test; known hypersensitivity or idiosyncrasy to the sympathomimetic amines or glaucoma or any disabling, severe, OR unstable medical condition that, in the opinion of the study physician, precludes safe participation or the ability to provide fully informed consent; 2. Any severe or unstable co-morbid substance use disorder that, in the opinion of the study physician, precludes safe participation in the study; 3. Participants with Opioid Use Disorder (OUD) who have been on Opioid Agonist Therapy (OAT) for \\\u003C 12 weeks, and not yet at stabilization dose, or at stabilization dose \\\u003C 4 weeks; 4. Current or history of any serious psychiatric disorder (e.g., bipolar disorder, pre-existing psychosis, schizophrenia) that, in the opinion of the study physician, precludes safe participation in the study; 5. History of a severe adverse event, hypersensitivity or known allergic reaction to LDX or other amphetamine drugs OR hypersensitivity to the sympathomimetic amines; 6. Pregnant, nursing, or planning to become pregnant during the study period; 7. Planned extended absence during study period (e.g., pending legal action, surgery, incarceration, inpatient residential program) in the opinion of the study physician that might prevent completion of the study; 8. Use of an investigational drug for stimulant use disorder during the 30 days prior to screening, confirmed via self-report OR pharmacy records; 9. Currently receiving contingency management for the treatment of stimulant use disorder in the 4 weeks prior to screening, confirmed via self-report OR site records; 10. Use of prescribed amphetamine-type medication OR medication for the treatment of stimulant use disorder (e.g., methylphenidate, modafinil, bupropion) in the 4 weeks prior to screening; 11. Current or anticipated need for treatment with any medication that may interact with LDX (e.g., proton pump inhibitors, monoamine oxidase inhibitors \\[MAOIs\\]) used currently or within the past 14 days AND that would preclude study participant at the discretion of the study physician",{"count":480,"type":22},440,[25],"The goal of this clinical trial is to learn if administering a high dose stimulant with Contingency Management reduces days of use in adults who use methamphetamine better than the usual treatment provided by the clinic.\n\nThe main questions the trial aims to answer are:\n\nIs a high dose stimulant better than a placebo and usual treatment at helping reduce the number of days they use methamphetamine? Is a high dose stimulant with contingency management better than placebo and usual treatment at helping people reduce the number of days they use methamphetamine?\n\nParticipants will be placed randomly into one of four groups:\n\n1. Usual treatment and placebo\n2. Usual treatment, placebo and contingency management\n3. Usual treatment and high dose stimulant\n4. Usual treatment, high dose stimulant and contingency management\n\nParticipation includes the following:\n\n1. Participants will receive medication or placebo weekly for 15 weeks.\n2. Participants will attend the clinic for weekly treatment\n3. Participants will attend the clinic once every 2 weeks for study visits. Each visit will take about an hour to complete. At these visits, participants will be asked to provide a urine sample and complete questionnaires.",[452,453,159,28],[485,486],"Contingency Management","Treatment as Usual","2026-02-03",{"date":489,"type":39},"2026-02-05",{"date":491,"type":39},"2023-12-05",{"date":493,"type":22},"2028-04",{"name":471,"class":104},4,{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":23,"phases":505,"briefSummary":506,"conditions":507,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":47},"100607850","adaptation-of-the-eccclore-program-for-patients-with-addictive-and-traumatic-problems-100607850","NCT07193914","Adaptation of the ECCCLORE Program for Patients With Addictive and Traumatic Problems","Adaptation of the ECCCLORE Program for Patients With Addictive and Traumatic Problems: Feasibility and Acceptability","PEAT","Inclusion Criteria:\n\n* Patients with one or more addictions\n* ASSIST questionnaire score greater than or equal to 11 for alcohol consumption and greater than or equal to 4 for other substances.\n* Diagnosis of PTSD and\u002For CPTSD assessed using the ITQ scale.\n* Ability to understand, write, and read French\n* The patient must have given their free and informed consent\n* The patient must be a member or beneficiary of a health insurance plan\n\nExclusion Criteria:\n\n* The subject is participating in an interventional study involving a drug or medical device or a Category 1 study within 3 months prior to inclusion\n* The patient is under safeguard of justice or state guardianship\n* Patients with a psychotic disorder\n* Patients with severe cognitive impairment (MoCA \\\u003C 10)\n* Patients experiencing a manic or hypomanic episode\n* Patients experiencing a major depressive episode\n* Patients participating in an interventional study involving a drug or medical device or a Category 1 RIPH within 3 months prior to inclusion\n* Pregnant, parturient, or breastfeeding woman",{"count":114,"type":22},[59],"Complex posttraumatic stress disorder (cPTSD) is characterized by chronic and pervasive disruptions in emotion regulation, identity, and relationships following prolonged or multiple exposures to trauma. It is frequently found in patients with addiction. Individuals with cPTSD have more severe addiction. In addition, the co-occurrence of these two disorders is often associated with certain transdiagnostic processes such as impulsivity. Indeed, PTSD is linked to a higher impulsivity score, which in turn promotes increased substance use. A second process also associated with trauma and addiction is hostile attribution bias.\n\nThus, the trauma-addiction comorbidity generates multiple behavioral consequences (aggression, increased substance use, etc.) that impact patients' quality of life and represent an important treatment target. Many authors and clinicians have worked on creating treatment programs targeting both disorders, although group format treatment lacks empirical support. Indeed, even though the Seeking Safety program has been shown to be effective in reducing PTSD symptoms and substance use, there is currently no evidence to suggest its superiority.\n\nThe ECCCLORE program is a new 6-month cognitive behavioral therapy protocol initially designed for patients with borderline personality disorder, in whom addictive and traumatic issues are common. It is shorter than the standard dialectical behavioral therapy (DBT) program, which focuses on emotional dysregulation, impulsivity, and the traumatic dimension and lasts at least 1 year. It also integrates techniques from other approaches such as Acceptance and Commitment Therapy (ACT), which promotes the acceptance of internal experiences and engagement in actions consistent with values. It notably contains tools for developing emotional, distress tolerance, and interpersonal skills that could adapt to the difficulties generated by trauma and addiction. The objective of this research is to test the feasibility and acceptability of a 12-week ECCCLORE program adapted for patients with addictive and traumatic problems. The study investigators hypothesize that the implementation of this program will demonstrate satisfactory feasibility and acceptability.",[326,28,161,508],"CBT","2026-01-27",{"date":511,"type":39},"2026-01-28",{"date":513,"type":39},"2025-10-31",{"date":515,"type":22},"2027-03",{"name":517,"class":104},"Centre Hospitalier Universitaire de Nīmes",{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":447,"enrollmentInfo":525,"targetDuration":4,"studyType":23,"phases":527,"briefSummary":529,"conditions":530,"keywords":535,"overallStatus":238,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":47},"100618205","phase-4-impact-of-daridorexant-on-sleep-daytime-alertness-and-smoking-100618205","NCT07328594","Impact of Daridorexant on Sleep, Daytime Alertness, and Smoking","Impact of Daridorexant on Sleep, Daytime Alertness, and Smoking During Abstinence","INCLUSION\n\n1. Adult participants who are cigarette smokers, 18-55 years of age.\n2. Smokers: greater than 10 cigarettes\u002Fday.\n3. Smoking for 1 year or longer.\n4. Willingness to try to reduce or stay abstinent from cigarettes, smoking cessation aides (including nicotine gum or patches), smokeless tobacco, or electronic cigarettes for 3 weeks during the study.\n5. Willingness to monitor sleep at home with an external device and maintain a simple sleep and smoking diary for 3 weeks.\n6. Willingness to take a 5-min, mobile-based test 3X\u002Fday for 3 days\u002Fweek during the 3 weeks.\n7. Ability to travel to three Study Visits.\n8. Are willing to abstain from consuming grapefruit products during the study.\n9. Have an iPhone, best with iOS 17 or newer.\n\nEXCLUSION:\n\n1. Are currently taking any pharmaceutical drugs for smoking cessation, including: Nicotine patch or nicotine gum, buproprion (Wellbutrin, Zyban), varenicline (Chantix, Champix), other behavioral interventions such as cognitive behavioral therapy for smoking.\n2. Are currently using cannabis or alcohol for sleep. Are currently taking any pharmaceutical drugs for insomnia, such as eszopiclone (Lunesta), zaleplon (Sonata) or zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist) benzodiazepines, or opioids.\n3. Are currently taking stimulants commonly used for ADHD, such as methylphenidate (Ritalin Concerta, Daytrana) or amphetamines (Adderall, Dexedrine, Vyvanse).\n4. Are currently taking anti-seizure drugs, including lamotrigine, pregabalin (Lyrica), or gabapentin (Neurontin, Horizant, or Gralise).\n5. Have non-nicotine substance dependence (diagnosed with substance use disorder, including alcohol or cannabis use disorder (current cannabis use is acceptable, and past illicit drug use is acceptable if greater than 2 months prior to testing and does not meet current criteria for substance use disorders (SUDs) according to DSM-5).\n6. Have a major neurological disorder such as Parkinson's disease, epilepsy, Alzheimer's disease, multiple sclerosis, or any other serious neurological disorder.\n7. Have a history of serious psychiatric disorders including bipolar disorder, schizophrenia, or suicidality.\n8. Had a stroke or head injury which caused loss of consciousness for longer than three minutes in the past 1 year.\n9. Are pregnant or breastfeeding.\n10. Have been diagnosed with sleep apnea or other diagnosed sleep disorders such as narcolepsy.\n11. Have been diagnosed with thyroid problems.\n12. Have been diagnosed with COPD.\n13. Have been doing variable shift work in the past 1 month or traveled more than 1 time zone in past month.\n14. Are currently taking the following medications, supplements, or food: Daridorexant can interact with strong inhibitors of CYP3A4, which should be discussed with The Study Doctor's office (some of these include clarithromycin, diltiazem, erythromycin, itraconzale, ketoconazole, ritonavir, and verapamil).\n15. Have a BMI of 33 or higher.",{"count":526,"type":22},44,[528],"PHASE4","Tobacco use is the leading cause of preventable death in the U.S., with 480,000 deaths per year and 7.7 million deaths globally. A major clinical symptom associated with abstinence from both licit and illicit drugs is insomnia, which is a clinically verified, major risk factor for relapse. Roughly half of the 40 million smokers in the U.S. attempt to quit annually, with very low rates of success. One major hurdle is poor sleep quality during abstinence. Compounding the problem is that some pharmaceuticals to help reduce smoking can increase insomnia. Poor sleep is recognized as a major impediment to maintaining abstinence from several drugs of abuse, including nicotine. Blockers of orexin have recently been proposed as a promising therapy for smoking cessation. Insomnia has been reported in up to 40% of smokers, and 80% report regular sleep disturbances, which can be amplified during abstinence. A new orexin blocker, daridorexant, was FDA approved within the past two years for the treatment of insomnia, and while it has been tested in healthy individuals with insomnia, it has not been tested in smokers, who suffer from insomnia, particularly during the withdrawal phase when trying to quit. Daridorexant has an improved profile of beneficial effects for those with insomnia, the most notable advantage being its shorter duration of action that promotes daytime alertness, which is problematic for both active smokers and smokers during withdrawal. Poor sleep leads to daytime sleepiness, which often leads to smoking to maintain alertness.",[531,431,532,28,161,533,534],"Smoking","Tobacco","Insomnia","Sleep",[533,536,531,431,532,534,28,537],"Daridorexant","Substance use disorders","2026-01-07",{"date":540,"type":39},"2026-01-09",{"date":542,"type":22},"2026-02-10",{"date":544,"type":22},"2027-09-30",{"name":546,"class":104},"Legacy Health System",{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":553,"eligibilityCriteria":554,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":555,"targetDuration":557,"studyType":210,"phases":4,"briefSummary":558,"conditions":559,"keywords":560,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":47},"100612160","understanding-the-long-term-paths-of-people-with-addictions-100612160","NCT07249970","Understanding the Long-term Paths of People With Addictions","Trajectories of People With Substance or Behavioral Addictions in Contact With the Healthcare System: Medical, Neurobiological, Sociological, and Psychological Characteristics. Multicenter, Multidisciplinary Prospective Study.","ADDICT AQUI","Inclusion Criteria:\n\n* Seeking treatment for substance or behavioral addiction at one of the inclusion centers, with more than one month to wait before treatment begins\n* Presenting with at least one substance or behavioral addiction (according to DSM5 criteria)\n\nExclusion Criteria:\n\n* Condition incompatible with understanding assessment tools\n* Difficulties understanding and\u002For writing French\n* Person unable to give personal consent",{"count":556,"type":22},10000,"5 Years","The study is an open prospective cohort study. Participants are assessed at the start of their care in an addiction treatment unit using the Addiction Severity Index (ASI) and the Mini International Neuropsychiatric Interview (MINI), which are routinely conducted in these centers for individuals with substance use or behavioral disorders. After the study protocol is explained, the evaluator checks eligibility criteria, interested participants provide their written informed consent. The evaluator invites participants to complete self-administered questionnaires at home, which are returned during a session that also includes cognitive testing. Follow-up interviews are scheduled at 3 months, 6 months, and every 6 months thereafter.",[366,399,28],[28,561,562],"addictive behavior","addiction disorders","2025-11-24",{"date":565,"type":39},"2025-11-25",{"date":567,"type":39},"2002-03-12",{"date":569,"type":22},"2035-12-31",{"name":571,"class":572},"Centre Hospitalier Charles Perrens, Bordeaux","OTHER_GOV",{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":577,"acronym":4,"eligibilityCriteria":578,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":579,"targetDuration":4,"studyType":23,"phases":581,"briefSummary":582,"conditions":583,"keywords":588,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":350},"100524027","syringe-service-based-telemedicine-and-social-network-driven-hiv-prevention-service-implementation-100524027","NCT06103370","Syringe Service Based Telemedicine and Social Network Driven HIV Prevention Service Implementation","Inclusion Criteria:\n\nInclusion criteria for index participants:\n\n* Aged 18 or older\n* Self-reported injection drug use in the prior month\n* Accessed services at the SSP in the prior 3 months\n* Willing to undergo training and attend weekly booster group sessions\n* Able to recruit at least 1 drug use Network Member (NM) into study\n* Willing to talk with peers about PWID topics such as HIV prevention and care\n* Not previously enrolled in the study as index or NM\n* English-speaking\n\nInclusion criteria for network member participants:\n\n* Aged 18 or older\n* Self-reported injection drug use in the prior month\n* Have a valid coupon or able to recall the 3-digit ID number\n* Not previously enrolled in the study as index or NM\n* English-speaking\n\nExclusion criteria:\n\n• Individuals lacking the capacity to consent",{"count":580,"type":22},360,[59],"The goal of this clinical trial is to evaluate the effectiveness of a social network intervention to recruit people who inject drugs and their networks for HIV testing and linkage to HIV prevention and treatment services in Maryland. Study aims are to determine the effectiveness of a social network driven intervention to increase:\n\n* HIV testing (primary);\n* PrEP knowledge;\n* Uptake of HIV services and pre-exposure prophylaxis (PrEP);\n* Uptake of medication for opioid use disorder (MOUD) initiation.\n\nEligible participants who access syringe service programs (SSPs) serving two counties in Maryland and their risk network members (NMs) will be recruited using an established network inventory and coupon recruitment method. When an index successfully recruits NMs, the index-NM cluster will be randomized to either a peer-educator intervention arm or an equal-attention control arm. Index participants randomized to the peer-educator intervention arm will complete a training program adapted with stakeholder input to context that emphasizes effective communication, frequent HIV testing, and awareness of evidence-based HIV prevention and treatment services. An important innovation to the network intervention will be training indexes to use and distribute HIV self-test kits and naloxone to their NMs. Index participants randomized to the equal-attention control arm will receive training sessions focused on the opioid overdose epidemic and will not include any training to serve as a peer educator. All participants (indexes and NMs) will complete study assessments at baseline and at 3 and 9 months. We will compare the peer-educator intervention group and the equal-attention control group on rates of HIV testing, knowledge of PrEP options and resources, and rates of initiation of HIV treatment, PrEP, and MOUD treatment since the previous assessment (past 3 or 6 months).",[584,161,28,585,586,587],"HIV Infections","Opioid Use","Drug Use","Intravenous Drug Usage",[589,590,591],"Injection Drug Use","HIV Prevention","Social Networks","2025-11-06",{"date":594,"type":39},"2025-11-10",{"date":596,"type":39},"2025-10-28",{"date":598,"type":22},"2028-11",{"name":600,"class":104},"Johns Hopkins University",{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":605,"acronym":4,"eligibilityCriteria":606,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":607,"targetDuration":4,"studyType":23,"phases":608,"briefSummary":609,"conditions":610,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":617,"locationsCount":47},"100444049","tdcs-and-cognitive-training-combined-for-aud-tango-100444049","NCT05062369","Tdcs And cogNitive traininG cOmbined for AUD (TANGO)","Inclusion Criteria:\n\n* Meet the Diagnostic and Statistical Manual of Mental Disorders diagnostic criteria for AUD\n* Abstinent from alcohol use\n* Must have the intention to remain in the Lodging Plus program until the end of the intervention portion of the study.\n\nExclusion Criteria:\n\n* Any medical condition or treatment with neurological sequelae (i.e. stroke, tumor, loss of consciousness\\>30 min, HIV)\n* A head injury resulting in a skull fracture or a loss of consciousness exceeding 30 minutes (i.e., moderate or severe TBI)\n* Any contraindications for tDCS or MRI scanning (tDCS contraindication: history of seizures; MRI contraindications; metal implants, pacemakers or any other implanted electrical device, injury with metal, braces, dental implants, non-removable body piercings, pregnancy, breathing or moving disorder)\n* Any primary psychotic disorder (e.g. schizophrenia, schizoaffective disorder); Participants with other treated and stable psychiatric disorders will be included\n* Presence of a condition that would render study measures difficult or impossible to administer or interpret\n* Primary current substance use disorder diagnosis on a substance other than alcohol except for caffeine or nicotine\n* Clinical evidence for Wernicke-Korsakoff syndrome\n* Left-handedness\n* Entrance to the treatment program under a court mandate",{"count":421,"type":22},[59],"The overarching goal of this project is to expand the traditional expertise in non-invasive neuromodulation at the University of Minnesota towards developing novel paired-neuromodulation approaches using transcranial direct current stimulation (tDCS) for new treatments for alcohol use disorder (AUD) that support long-term abstinence. This study will allow the investigators to discern whether the pairing of dorsolateral prefrontal cortex (DLPFC) stimulation and cognitive training can lead to improved treatment outcomes as it pertains to executive functioning and maintenance of abstinence. This paired-neuromodulation approach can potentially be used as a therapeutic intervention to decrease relapse probability in addiction. The long-term goal is to develop new addiction treatments that support long-term abstinence. The exploratory goal of this research is to associate genotypes and epigenetic changes with variations in intervention response and clinical outcome. Individual differences in baseline genetic profiles or epigenetic changes over the course of treatment could be associated with treatment response variability.",[29,28],"2025-10-07",{"date":613,"type":39},"2025-10-09",{"date":615,"type":39},"2022-03-03",{"date":544,"type":22},{"name":618,"class":104},"University of Minnesota",{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":624,"acronym":625,"eligibilityCriteria":626,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":627,"enrollmentInfo":628,"targetDuration":4,"studyType":23,"phases":630,"briefSummary":631,"conditions":632,"keywords":634,"overallStatus":238,"whyStopped":4,"lastUpdateSubmitDate":636,"lastUpdatePostDateStruct":637,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":47},"100603023","can-selfcompassion-training-reduce-alcohol-consumption-in-patients-with-alcohol-use-disosrder--100603023","NCT07131124","Can Selfcompassion Training Reduce Alcohol Consumption in Patients With Alcohol Use Disosrder ?","Can Selfcompassion Training Reduce Alcohol Consumption in Patients With Alcohol Use Disosrder ? Randomized Controlled Trial","COMPAL","Inclusion Criteria:\n\n* Adults aged 18 to 75 years.\n* Subjects meeting DSM-5 criteria for Alcohol Use Disorder (AUD).\n* Subjects receiving outpatient care in addiction services, CSAPA, CMP, day hospitals, mental health care institutions, community mental health centers.\n* Subjects affiliated with the social security system.\n* Subjects who have a good understanding of French languague, allowing them to provide informed consent, respond to self-questionnaires, and participate in the MSC program.\n\nExclusion Criteria:\n\n* Subjects unable to understand the questionnaires.\n* Subjects presenting moderate or severe suicidal ideation (assessed by the Suicide item of the MINI scale).\n* Subjects with a score \\\u003C10 on the MoCA version 7.1 test.\n* Subjects admitted to inpatient units (since hospitalization alters alcohol consumption).\n* Subjects unable to provide informed or voluntary consent to participate in the study.\n* Subjects under guardianship or curatorship.","75 Years",{"count":629,"type":22},152,[59],"The objective of this interventional study is to evaluate the effectiveness of the Mindful Self-Compassion (MSC) program in reducing alcohol consumption in a population of individuals with Alcohol Use Disorder (AUD), six months after the intervention. The MSC program was designed to enhance self-compassion skills. It has demonstrated a mediating effect on symptoms of stress, depression, and anxiety, which are known to contribute to the maintenance of AUD.\n\nOutpatients with AUD will be included after providing informed consent and will be randomized into two groups (MSC+TAU vs TAU). The follow-up includes 13 visits over a 9-month period, with group sessions according to allocation. Three follow-up visits are scheduled up to six months after the end of the sessions. Participants will complete several scales and surveys (AUDIT, TLFB, SCS, HAD, SSS-S, TOSCA-3, AQoLS, MAAS, Fagerström, CUDIT-R, EVA craving).",[28,366,633,62],"Alcohol Use Disorders",[635,633],"Self-compassion","2025-08-12",{"date":638,"type":39},"2025-08-20",{"date":640,"type":22},"2025-10",{"date":642,"type":22},"2027-10",{"name":644,"class":104},"Etablissement Public de Santé Barthélemy Durand",{"id":646,"slug":647,"hasResults":12,"nctId":648,"briefTitle":649,"officialTitle":650,"acronym":651,"eligibilityCriteria":652,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":653,"targetDuration":4,"studyType":23,"phases":655,"briefSummary":656,"conditions":657,"keywords":658,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":660,"lastUpdatePostDateStruct":661,"startDateStruct":663,"completionDateStruct":665,"leadSponsor":667,"locationsCount":47},"100418742","efficacy-of-a-smartphone-app-designed-to-manage-craving--individual-predictors-of-substance-useaddictive-behavior-100418742","NCT04732676","Efficacy of a Smartphone App. Designed to Manage Craving & Individual Predictors of Substance Use\u002FAddictive Behavior","Efficacy of a Smartphone App Designed to Manage Craving and Individual Predictors of Substance Use \u002F Addictive Behavior Among Individuals With Addictive Disorders","CRAVINGMANAGER","Inclusion Criteria:\n\n* Participants requesting help for substance or behavioral addiction in one of the participating specialized addiction treatment centers, and with more than 1-month-delay before treatment admission\n* Age \\>= 18 years of age\n* With at least one substance or behavioral addiction (DSM-5 criteria)\n* Affiliated person or beneficiary of a social security scheme.\n* Free, informed and written consent signed by the participant and the investigator\n\nExclusion Criteria:\n\n* Medical, psychiatric or addiction condition that warrants immediate treatment intervention\n* Patients with somatic, cognitive or other disorders preventing the use of the device (deafness, impaired vision, illiteracy....)\n* Difficulty in understanding and \u002F or writing French\n* Not familiar with the use of smartphone\n* Individuals participating in another study that includes an ongoing exclusion period\n* Be deprived of liberty due to an ongoing legal procedure\n* Individuals under legal protection\n* Be under guardianship or under curatorship",{"count":654,"type":22},274,[59],"Test the Efficacy of a smartphone application designed to manage craving and individual predictors of substance use \u002F addictive behavior among individuals with addictive disorders",[28],[659],"craving","2025-08-11",{"date":662,"type":39},"2025-08-14",{"date":664,"type":39},"2023-03-01",{"date":666,"type":22},"2028-07-31",{"name":571,"class":572},{"id":669,"slug":670,"hasResults":12,"nctId":671,"briefTitle":672,"officialTitle":673,"acronym":674,"eligibilityCriteria":675,"healthyVolunteers":12,"sex":17,"minAge":676,"maxAge":288,"enrollmentInfo":677,"targetDuration":679,"studyType":210,"phases":4,"briefSummary":680,"conditions":681,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":682,"lastUpdatePostDateStruct":683,"startDateStruct":685,"completionDateStruct":687,"leadSponsor":689,"locationsCount":47},"100486084","trajectories-and-reactions-of-users-and-relatives-consulting-french-youth-addiction-services-100486084","NCT05609474","Trajectories and Reactions of Users and Relatives Consulting French Youth Addiction Services","Trajectories and Reactions of Users and Relatives Consulting French Youth Addiction Services (Consultations Jeunes Consommateurs)","TRYAD","Inclusion Criteria:\n\nFor users :\n\n* First consultation in CJC\n* From 12 to 25 years old\n\nFor caregivers :\n\n* First consultation in CJC (with or without the youth) or second consultation if accompanying a user\n* ≥ 18 ans\n\nExclusion Criteria:\n\n* inability to reach by phone\n* Insufficient french level","12 Years",{"count":678,"type":22},1430,"1 Year","In France, the \"Consultations Jeunes Consommateurs\" (CJC) are the services specialized in the reception of young people for addiction problems. There are more than 500 CJCs throughout France. Depending on the situation, the CJC develops an early intervention strategy aimed either at reducing the risk of developing an addiction or at accelerating entry into appropriate care. The CJCs also meet with family members or professionals who may also independently request help or advice.\n\nSet up by the State since 2004, the action of the CJCs has never been formally evaluated. Only descriptive studies, carried out by the French Observatory of Drugs and Drug Addiction (OFDT), have made it possible to better understand the profile of people who consult CJCs. However, no longitudinal study has yet been carried out to understand the factors associated with the overall evolution of users consulting CJCs, nor with the level of satisfaction of users and those around them. Such objectives are complex, due to the diversity of situations encountered in CJCs and the heterogeneity of the CJCs themselves.",[28],"2025-07-29",{"date":684,"type":39},"2025-07-30",{"date":686,"type":39},"2023-02-15",{"date":688,"type":22},"2028-10-01",{"name":690,"class":104},"Hôpital le Vinatier",{"id":692,"slug":693,"hasResults":12,"nctId":694,"briefTitle":695,"officialTitle":696,"acronym":697,"eligibilityCriteria":698,"healthyVolunteers":54,"sex":17,"minAge":699,"maxAge":4,"enrollmentInfo":700,"targetDuration":4,"studyType":210,"phases":4,"briefSummary":702,"conditions":703,"keywords":704,"overallStatus":238,"whyStopped":4,"lastUpdateSubmitDate":707,"lastUpdatePostDateStruct":708,"startDateStruct":710,"completionDateStruct":712,"leadSponsor":714,"locationsCount":47},"100577452","prevalence-of-problematic-use-of-social-media-100577452","NCT06798480","Prevalence of Problematic Use of Social Media","Prevalence of Problematic Use of Social Media in the General PopuLation","PURPLE","Inclusion Criteria:\n\n* Aged 13 years or older.\n* Resident in France and French-speaking.\n* Does not object to participating in the study, and, for minors, whose parents also do not object to their participation.\n\nExclusion Criteria:\n\n* Unable to understand and complete the questionnaire (e.g., non-French-speaking).","13 Years",{"count":701,"type":22},1000,"In 2023, French individuals spend an average of two hours per day on social media platforms (SM), primarily Facebook, TikTok, X, YouTube, Instagram, and Snapchat. While social media offers undeniable benefits, it also raises concerns about its impact on mental health and well-being. These impacts remain poorly understood, partly due to the diversity of social media uses and motivations, which do not have uniform effects on health. For instance, studies have shown that \"active\" use of social media (e.g., content creation) is associated with higher well-being, whereas \"passive\" use (e.g., content scrolling) is linked to lower well-being.\n\nThis challenge in understanding the variety of social media uses and their consequences has direct clinical implications. Clinicians working in pediatrics, child psychiatry, and addiction medicine are increasingly confronted with patients struggling to manage their social media use. However, they lack clear diagnostic criteria to differentiate between normal and problematic use, as well as specific tools tailored to address potential disorders.\n\nMoreover, in France, there is no existing estimate of the proportion of the general population affected by problematic social media use.\n\nThis study aims to establish the prevalence of problematic use of social media in France. The investigators hypothesize that the prevalence will be close to 10%, which is the prevalence that has been found in other European countries in previous studies.",[591,28],[705,706,295],"Problematic use","social media","2025-02-28",{"date":709,"type":39},"2025-03-05",{"date":711,"type":22},"2025-04-01",{"date":713,"type":22},"2025-07-01",{"name":715,"class":104},"Hospices Civils de Lyon"]